Briakinumab vs placebo
Serious adverse events (Panaccione 2010) · induction of remission in Crohn's disease
Briakinumab showed no clear difference in serious adverse events (Panaccione 2010) compared with placebo (low certainty).
1 finding from 1 review
- Anti‐IL‐12/23p40 antibodies for induction of remission in Crohn's disease 2016 · Cochrane Headline outcomes onlyRR 0.52 [0.17, 1.61]1 study · 246 participantsLow